SVB Leerink initiated coverage on Aldeyra Therapeutics
$ALDX
Biotechnology: Pharmaceutical Preparations
Health Care
SVB Leerink initiated coverage of Aldeyra Therapeutics with a rating of Outperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/3/2024 | $10.00 | Perform → Outperform | Oppenheimer |
| 4/2/2024 | $10.00 | Buy | H.C. Wainwright |
| 4/27/2022 | $15.00 | Buy | H.C. Wainwright |
| 12/21/2021 | $25.00 → $21.00 | Buy | Citigroup |
| 12/21/2021 | $24.00 → $15.00 | Outperform | SVB Leerink |
4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
Oppenheimer upgraded Aldeyra Therapeutics from Perform to Outperform and set a new price target of $10.00
H.C. Wainwright resumed coverage of Aldeyra Therapeutics with a rating of Buy and set a new price target of $10.00
H.C. Wainwright resumed coverage of Aldeyra Therapeutics with a rating of Buy and set a new price target of $15.00
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune‑mediated and metabolic diseases, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. Per FDA agreement, the only new clinical data included in the resubmitted NDA were from the recently completed dry eye chamber trial, which achieved the primary endpoint. "Consistent with a number of clinical trials that suggest the potential of reproxalap to ra
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference in New York, New York. Dr. Brady's conversation with Clara Dong is scheduled to begin at 4:20 p.m. ET Thursday, June 5, 2025. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. Following the fireside chat, the webcast will be archived for 90 days. About Aldeyra
In a Dry Eye Chamber Trial, Reproxalap Was Statistically Superior (P=0.002) to Vehicle in Primary Endpoint of Ocular Discomfort Aldeyra Believes the Dry Eye Chamber Trial Results, including No Notable Differences in Baseline Scores Across Treatment Arms, Potentially Address FDA Feedback following the Prior NDA Review New Drug Application Resubmission Is Anticipated Mid‑2025 A Recently Completed Dry Eye Disease Field Trial, which Was Numerically Supportive of Reproxalap and Consistent with Prior Field Trials, Did Not Reach Statistical Significance, and Is Expected to be Submitted to the Planned NDA Resubmission as Supportive Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechno